Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids
Authors:
- 15 March 2016
- journal article
- case report
- Published by Springer Nature in International Journal of Hematology
- Vol. 103 (6) , 718-723
Abstract
TAFRO syndrome is a rare variant type of multicentric Castleman disease, which is characterized by thrombocytopenia, anasarca, reticulin fibrosis of bone marrow, renal dysfunction and organomegaly. Here, we report a case of TAFRO syndrome that was successfully treated with tocilizumab. A 50-year-old man, who presented with fever, epigastric pain, abdominal fullness, and massive edema of the extremities, was admitted to our hospital. Computed tomography revealed bilateral pleural effusions, ascites, and lymphadenopathy. Laboratory data showed renal dysfunction, anemia, and thrombocytopenia. Examination of bone marrow and cervical lymph nodes led to a diagnosis of hyaline vascular-type Castleman disease. The level of serum interleukin (IL)-6 was extremely high. TAFRO syndrome was finally diagnosed. The patient was treated weekly with tocilizumab, an anti-IL-6 receptor antibody and steroids. In 4 weeks, all symptoms disappeared and serum IL-6 level returned to normal. Activity of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which was significantly decreased (9.9 %) prior to treatment, increased after treatment with tocilizumab. The present case suggests that tocilizumab is an effective therapeutic agent for TAFRO syndrome. We suggest that hypercytokinemia in TAFRO syndrome inhibits ADAMTS13 activity, thereby inducing thrombotic microangiopathy.Keywords
This publication has 21 references indexed in Scilit:
- HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapyBlood, 2014
- Update on von Willebrand factor multimersBlood Coagulation & Fibrinolysis, 2014
- The Clinical Implications of ADAMTS13 Function: The Perspectives of HaemostaseologistsThrombosis Research, 2013
- Castleman's Disease: From Basic Mechanisms to Molecular TherapeuticsThe Oncologist, 2011
- Membranoproliferative glomerulonephritis in the setting of multicentric angiofollicular lymph node hyperplasia (Castleman's disease) complicated by Evan's syndromeJournal of Clinical Pathology, 2010
- Castleman DiseaseAdvances in Anatomic Pathology, 2009
- Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cellsJournal of Thrombosis and Haemostasis, 2008
- Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flowBlood, 2004
- Systemic Castleman's disease in association with Evan's syndrome and vitiligoMedical and Pediatric Oncology, 1990
- Case 40231New England Journal of Medicine, 1954